Last updated on August 2019

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Brief description of study

Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.

Clinical Study Identifier: NCT02635061

Find a site near you

Start Over

Virginia Cancer Specialists, PC

Fairfax, VA United States
  Connect »